UK giving second dose of Pfizer-BioNTech vaccine up to 12 weeks after the first, but WHO recommends a shorter gap.
London, United Kingdom – When Ayesha Sharieff, a general practitioner in a south London surgery, administered the first COVID vaccines to her patients earlier this month, she was overjoyed.
“It was the best afternoon I’ve spent for a long time,” said Sharieff, who has been a doctor for 20 years. “After all these tough times we’ve been through recently, it was such a pleasure. I wanted to jump on top of my car and honk the horn.”
Each day, Sharieff and her team vaccinate up to 300 patients, currently focusing on elderly people from the area’s diverse urban population as a priority, as part of the United Kingdom’s rapid vaccine roll-out.
“I recently vaccinated a Caribbean nurse working in infectious diseases who must have been 88,” said Sharieff. “It just felt like such an honour to be doing that for her. I had tears in my eyes.”
The UK has earned cautious early praise for its vaccine roll-out, which has seen it produce double the number of vaccinations per person per day of any other European country.
This marks a significant turnaround because with the highest COVID-19 death toll in Europe, the UK government faces high levels of criticism for failing to contain the virus.
More than six million people in the UK have received a first dose of a COVID-19 vaccine to date, as part of the largest vaccination programme in British history. The National Health Service (NHS) has vaccinated more than half of those aged 80 and over and more than half of elderly care home residents, both considered priorities, according to the Department of Health and Social Care.
Once those priorities have been treated, the UK will offer the vaccine to everyone over 50 and then everyone aged over 18.
British Prime Minister Boris Johnson’s government has said it plans to offer a first dose of vaccine to every adult in Britain, who make up 51 million of its total 67.5 million population, by September.
It will soon begin a trial of 24-hour injections as it continues to add more vaccination sites to increase the pace of delivery.
Good logistics planning and significant financial investment have underpinned the early positive vaccination numbers, according to Sarah Schiffling, a supply chains expert at Liverpool John Moores University.
“We can’t underestimate the fact the UK is devoting nearly £12 billion to the purchase, manufacture and roll-out of the vaccine,” she told Al Jazeera. “But the UK is seeing the benefit of having a coordinated approach. It’s started out really well and gotten up to quite a volume of patients vaccinated very quickly and that is very promising.”
Schiffling believes the centralised nature of the NHS as well the UK’s “far-reaching delivery network” – which spans from local GPs to mass vaccination centres – has also played a key role. “It’s a flexible, scalable system and that’s been working really well so far,” she explained.
The NHS, unlike some countries that have a federal approach, has departments already in place for bulk purchasing, says Schiffling, and the UK invested quickly into materials such as syringes that are now in high demand.
“One system can work along the supply chain, and that’s worked to the UK’s advantage here,” she said.
The UK became the first Western country to license a COVID-19 vaccine on December 2 when the medicines regulator approved the Pfizer-BioNTech jab. Since then, it has also approved vaccines produced by Oxford-AstraZeneca and Moderna, but doses of the latter are not expected for months.
But unlike other nations, the UK has decided to increase the time between vaccine doses given to people from 21 days to up to 12 weeks, a decision that is thought to mean more people will get their first dose more quickly.
“The UK has prioritised getting people the first doses,” said Mark Jit, a professor of vaccine epidemiology at the London School of Hygiene and Tropical Medicine. “This has enabled more people to be vaccinated quickly. From what we know about vaccines, the first dose gives quite good protection, especially with the Astra-Zeneca vaccine. It’s not that the second dose will be dropped entirely.”
Professor Jit says the UK’s history of previous successful campaigns has also helped the rapid roll-out.
“The UK has an advantage because it has a long history of successful vaccine introductions,” he said, pointing to the introduction of the Shingles vaccine to adults in 2013, the HPV vaccine for adolescents in 2008 and national flu campaigns. “Part of it is also good communication, so there is good public confidence in vaccines.”
But Jit added that while success in the UK’s vaccine roll-out is good news, the issue will persist while all countries still need vaccine supplies.
“This is a global issue and the pandemic won’t be solved until we address those worldwide concerns,” he said.
With England in a third national lockdown since January 2 after a highly transmissible variant helped push the number of people hospitalised with COVID-19 to record highs, for some, vaccination can’t come any sooner.
The UK is now rapidly approaching 100,000 coronavirus-related deaths, marking the worst death toll in Europe and the fifth-highest number worldwide, and some 50,000 health workers are off work due to COVID-19 infections and exposure quarantines.
“This vaccine roll-out has been one of the most uplifting things in my career,” said Sharieff, the GP. “But as it continues we will have to vaccinate larger, more diverse patient groups. We need to make sure everyone is protected equally.”